<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) October 15, 1996
----------------
BOSTON LIFE SCIENCES, INC.
---------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826
- --------------------- ------ --------------------
(State or other jurisdiction (Commission File No.) (I.R.S. Employer
of incorporation or Identification No.)
organization)
33 Newbury Street, Suite 300
Boston, Massachusetts 02116
- ---------------------------------------- ----------
(Address of principal executive offices) Zip Code
Registrant's telephone number, including area code (617) 425-0200
---------------
<PAGE>
Item 5. Other Events.
-------------
On October 15, 1996, Boston Life Sciences, Inc., a company engaged in the
research and development of novel treatments for cancer, autoimmune diseases,
and central nervous system disorders, announced that the Company had received
notices of allowance for two patent applications licensed from Children's
Hospital and Harvard University. The notice of allowances pertain to patent
applications covering the Company's Central Nervous System growth factor,
Axogenesis Factor 1 (AF1), and the use of transcription factors to control the
expression of MHC Class II molecules for the potential treatment of autoimmune
diseases.
These notices of allowances strengthen the company's position in these two
important areas. The allowed patent on transcriptional control of MHC Class II
molecules, together with the recent licensing of patent applications covering
C-maf and NIP-45, positions the Company as a potential leader in the field of
immune system regulation. The Company is hopeful that its licenses to and
development of these important discoveries will eventually yield novel products
for the treatment of autoimmune diseases and allergies. The Company believes
that AF1 is a potential treatment for stroke and spinal cord injuries. The
Company continues to make substantial preclinical development progress with AF1
and hopes to be able to begin to bring it into human clinical testing in 1998.
Item 8 Exhibits.
--------
The following Exhibits are filed as part of this report on Form 8-K
99.1 Press Release, dated October 15, 1996.
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: October 22, 1996 By: /s/ Joseph Hernon
------------------
Joseph Hernon
Chief Financial Officer
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit No. Page
- ----------- ----
<S> <C>
99.1 Press Release, dated October 15, 1996 5
</TABLE>
<PAGE>
Exhibit 99.1
***FOR IMMEDIATE RELEASE***
BOSTON LIFE SCIENCES RECEIVES NOTICE OF TWO PATENTS
COVERING AXOGENESIS FACTOR 1 (AF1) AND AUTOIMMUNE PROGRAM
Boston, Mass - October 15, 1996-- Boston Life Sciences, Inc. (NASDAQ: BLSI)
announced that the Company had received notices of allowance for two patent
applications licensed from Children's Hospital and Harvard University. The
notice of allowances pertain to patent applications covering the company's
Central Nervous System growth factor, Axogenesis Factor 1 (AF1), and the use of
transcription factors to control the expression of MHC Class II molecules for
the potential treatment of autoimmune diseases.
"These notices of allowances strengthen our position in these two important
areas. We believe that the allowed patent on transcriptional control of MHC
Class II molecules, together with the recent licensing of patent applications
covering C-maf and NIP-45, positions the Company as a potential leader in the
field of immune system regulation. We are hopeful that its licenses to and
development of these important discoveries will eventually yield novel products
for the treatment of autoimmune diseases and allergies," stated Dr. Marc Lanser,
Chief Scientific Officer of BLSI.
"We continue to be very excited about AF1 as a potential treatment for stroke
and spinal cord injuries, so we are obviously gratified to have received a
patent allowance on this important molecule. We continue to make substantial
preclinical development progress with AF1 and hope to be able to begin to bring
it into human clinical testing in 1998," added Dr. Lanser.
BLSI is engaged in the research and development of novel treatments for cancer,
autoimmune diseases, and central nervous system disorders. BLSI's products in
clinical trials or in pre-clinical development include the above-mentioned
anti-angiogenesis factor for the treatment of solid tumors; Axogenesis
Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM),
a radioimaging agent for the diagnosis of Parkinson's Disease; THERAFECTIN(R)
for the treatment of Rheumatoid Arthritis; and transcription factors to control
the expression of molecules associated with autoimmune disease and allergies.
For additional information contact:
Marc E. Lanser, M.D.
Chief Scientific Officer
617-425-0200
